Physician profile
Louis Yang
NPI 1710180377
$3,155.90
in general payments reported to CMS, 2019-2025
23 companies · $351 in 2025
The $351 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $179 · 2021: $311 · 2022: $383 · 2023: $691 · 2024: $579 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $742.68 | 2019-2025 | Rocklatan, Argos, Clareon |
| Sight Sciences, INC. | $359.53 | 2019-2024 | Omni Surgical System |
| Allergan, INC. | $312.90 | 2019-2021 | |
| Biotissue Holdings INC. | $234.46 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $224.78 | 2022-2025 | Acthar |
| Bausch & Lomb Americas INC. | $188.58 | 2023-2025 | Vyzulta, Miebo |
| Rayner Intraocular Lenses Limited | $138.07 | 2023-2024 | Rayone Spheric, Omidria, Rayone Emv |
| Abbvie INC. | $113.77 | 2023-2025 | Durysta, Lumigan |
| Harrow Eye, LLC | $113.52 | 2024-2025 | Iheezo, Vevye |
| Oyster Point Pharma, INC. | $112.08 | 2023-2024 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $109.11 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $84.63 | 2021 | |
| Sun Pharmaceutical Industries INC. | $83.66 | 2019-2021 | |
| Horizon Therapeutics Plc | $78.52 | 2022-2023 | Tepezza |
| Thea Pharma INC. | $64.84 | 2023-2025 | Iyuzeh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.42 | 2024 | Tepezza |
| Glaukos Corporation | $35.24 | 2023 | |
| Astellas Pharma US INC | $24.02 | 2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.44 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Iridex Corporation | $18.99 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $18.79 | 2025 | Tecnis Iol, Tecnis Iol |
| Ivantis, INC | $15.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.